Clinical Trials

20 results for Prostate Cancer


Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN)

  • Condition: Prostate Cancer
  • Intervention: Other: Standard of Care
  • Study ID: NCT03151629
View Trial

Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer

  • Condition: Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
  • Intervention: Biological: GnRH agonist/antagonist, Drug: Prednisone, Drug: Abiraterone Acetate, Drug: Enzalutamide
  • Study ID: NCT03016741
View Trial

Phase II Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)

  • Condition: Prostate Cancer Metastatic
  • Intervention: Drug: Rucaparib
  • Study ID: NCT03413995
View Trial

A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR)

  • Condition: Prostate Cancer
  • Intervention: Drug: Rucaparib
  • Study ID: NCT03533946
View Trial

Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

  • Condition: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Can
  • Intervention: Drug: Abiraterone Acetate, Drug: Antiandrogen Therapy, Drug: Cabazitaxel, Other: Laboratory Biomarker Analysis, Procedure: Orchiectomy, Other: Pharmacological Study, Drug: Prednisone
  • Study ID: NCT03419234
View Trial

Bone Response After Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients With Hormone Sensitive Metastatic Bone Disease: a Prospective, Phase II, Randomized, Multicenter Study

  • Condition: Prostate Cancer, Bone Metastases
  • Intervention: Drug: Zoledronic Acid, Drug: Enzalutamide
  • Study ID: NCT03336983
View Trial

A Phase 2 Trial of Radium Ra 223 Dichloride in Combination With Androgen Deprivation Therapy and Stereotactic Body Radiation Therapy for Patients With Oligometastatic Castration Sensitive Prostate Cancer

  • Condition: Prostate Adenocarcinoma
  • Intervention: Drug: Leuprolide Acetate, Drug: Goserelin Acetate, Radiation: Stereotactic Body Radiation Therapy, Radiation: Radium Ra 223 Dichloride, Other: Laboratory Biomarker Analysis
  • Study ID: NCT03361735
View Trial

Randomized Phase 1b/2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination With Intermittent Androgen Deprivation Therapy in Men With Hormone-Sensitive Prostate Cancer

  • Condition: Prostate Cancer, Adenocarcinoma of the Prostate
  • Intervention: Drug: Nivolumab, Drug: Degarelix, Drug: BMS-986253
  • Study ID: NCT03689699
View Trial

A Phase II Study of Olaparib and Durvalumab in Men With Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair

  • Condition: Prostate Cancer
  • Intervention: Drug: Olaparib, Drug: Durvalumab
  • Study ID: NCT03810105
View Trial

SAABR: Single-Arm Phase II Study of Abiraterone Acetate + Atezolizumab + Lupron and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men With Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer

  • Condition: Metastatic Prostate Cancer
  • Intervention: Drug: Atezolizumab, Drug: Abiraterone, Drug: Prednisone, Drug: Lupron, Radiation: Stereotactic Body Radiotherapy (SBRT)
  • Study ID: NCT04262154
View Trial

A Randomized Phase II Trial to Evaluate the Antitumor Activity of Enzalutamide and Talazoparib (PF-06944076) for the Treatment of Metastatic Hormone-naïve Prostate Cancer

  • Condition: Metastatic Prostate Cancer
  • Study ID: NCT04332744
View Trial

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Re

  • Condition: Metastatic Castrate Sensitive Prostate Cancer
  • Study ID: NCT04497844
View Trial

Advanced ChemoHormonal Therapy for Treatment Naïve Metastatic Prostate Cancer: Apalutamide and Abiraterone Acetate With Prednisone and Androgen Deprivation Therapy After Treatment With Docetaxel and Androgen Deprivation Therapy

  • Condition: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
  • Study ID: NCT04267887
View Trial

Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients - a GETUG-AFU Phase III Randomized Controlled Trial

  • Condition: Oligometastatic Hormone Sensitive Prostate Cancer
  • Study ID: NCT04115007
View Trial

A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, With an Observational Fol

  • Condition: Prostatic Neoplasms
  • Study ID: NCT04557059
View Trial

Phase 4 Study of Exploring Circulating Tumor DNA (ctDNA) of Metastatic Castration-sensitive Prostate Cancer (mCSPC) Patients Receiving Apalutamide in Japan

  • Condition: Metastatic Castration-sensitive Prostate Cancer
  • Study ID: NCT04601441
View Trial

Patients' Preferences in the Treatment of Hormone-sensitive Metastatic Prostate Cancer: a Discrete Choice Experiment

  • Condition: Prostate Cancer Metastatic, Radiotherapy Side Effect, Surgery, Urologic Cancer, Quality of Life, Patient Satisfaction, Health Care Utilization
  • Study ID: NCT04590976
View Trial

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide in Addition to Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Men With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

  • Condition: Prostatic Neoplasms
  • Study ID: NCT04736199
View Trial

TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

  • Condition: Prostate Cancer
  • Study ID: NCT04821622
View Trial

An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

  • Condition: Prostatic Neoplasms
  • Study ID: NCT04720157
View Trial